Adial Pharmaceuticals, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Adial Pharmaceuticals, Inc. (ADIL) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 16.51 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-14
- Adial Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 1.29M shares, a 550.16% increase year-over-year.
- Adial Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 198.06K shares, a 95.68% decline year-over-year.
- Adial Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 4.58M shares, a 73.84% decline year-over-year.
- Adial Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 17.51M shares, a 6.27% increase year-over-year.
- Adial Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 1.29M shares, a 551.39% increase from fiscal 2024.
- Adial Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 197.91K shares, a 94.23% decline from fiscal 2023.
- Adial Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 3.43M shares, a 390.09% increase from fiscal 2022.
- Adial Pharmaceuticals, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 699.85K shares, a 93.92% decline from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 16.51M shares 10-Q · filed 2026-08-14 | |||||||
| 2026-03-31 | 1.29M shares 10-Q · filed 2026-05-08 | |||||||
| 2025-12-31 | 1.29M shares 10-K · filed 2026-03-05 | |||||||
| 2025-09-30 | 27.80M shares 10-Q · filed 2025-11-13 | |||||||
| 2025-06-30 | 1.11M shares 10-Q · filed 2026-08-14 | 27.80M shares 10-Q · filed 2025-08-13 | ||||||
| 2025-03-31 | 198.06K shares 10-Q · filed 2026-05-08 | 4.95M shares 10-Q · filed 2025-05-14 | ||||||
| 2024-12-31 | 197.91K shares 10-K · filed 2026-03-05 | 4.95M shares 10-K · filed 2025-03-04 | ||||||
| 2024-09-30 | 4.56M shares 10-Q · filed 2025-11-13 | |||||||
| 2024-06-30 | 4.58M shares 10-Q · filed 2025-08-13 | |||||||
| 2024-03-31 | 4.58M shares 10-Q · filed 2025-05-14 | |||||||
| 2023-12-31 | 3.43M shares 10-K · filed 2025-03-04 | |||||||
| 2023-09-30 | 559.75K shares 10-Q · filed 2024-11-13 | |||||||
| 2023-06-30 | 733.39K shares 10-Q · filed 2024-08-13 | |||||||
| 2023-03-31 | 17.51M shares 10-Q · filed 2023-05-12 | |||||||
| 2022-12-31 | 699.85K shares 10-K · filed 2024-04-01 | 17.50M shares 10-K · filed 2023-03-30 | ||||||
| 2022-09-30 | 704.29K shares 10-Q · filed 2023-11-14 | 17.61M shares 10-Q · filed 2022-11-14 | ||||||
| 2022-06-30 | 659.72K shares 10-Q/A · filed 2023-10-30 | 16.49M shares 10-Q · filed 2022-08-15 | ||||||
| 2022-03-31 | 16.48M shares 10-Q · filed 2023-05-12 | |||||||
| 2021-12-31 | 11.50M shares 10-K · filed 2023-03-30 | |||||||
| 2021-09-30 | 11.56M shares 10-Q · filed 2022-11-14 | 11.60M shares 10-Q · filed 2021-11-15 | ||||||
| 2021-06-30 | 11.56M shares 10-Q · filed 2022-08-15 | |||||||
| 2021-03-31 | 11.46M shares 10-Q · filed 2022-05-16 | |||||||
| 2020-12-31 | 11.25M shares 10-K · filed 2022-03-28 | |||||||
| 2020-09-30 | 11.23M shares 10-Q · filed 2021-11-15 | |||||||
| 2020-06-30 | 11.46M shares 10-Q · filed 2021-08-12 | |||||||
| 2020-03-31 | 9.22M shares 10-Q · filed 2021-05-17 | |||||||
| 2019-12-31 | 8.26M shares 10-K · filed 2021-03-22 | |||||||
| 2019-09-30 | 8.09M shares 10-Q · filed 2020-11-13 | |||||||
| 2019-06-30 | 8.16M shares 10-Q · filed 2020-08-13 | 6.72M shares 10-Q · filed 2019-08-13 | ||||||
| 2019-03-31 | 8.13M shares 10-Q · filed 2020-05-14 | 6.73M shares 10-Q · filed 2019-05-13 | ||||||
| 2018-12-31 | 5.30M shares 10-K · filed 2020-03-20 | 5.05M shares 10-K · filed 2019-02-19 | ||||||
| 2018-09-30 | 5.25M shares 10-Q · filed 2019-11-14 | |||||||
| 2018-06-30 | 782.55K shares 10-Q · filed 2019-08-13 | |||||||
| 2017-12-31 | 482.56K shares 10-K · filed 2019-02-19 | |||||||
| 2017-09-30 | 656.84K shares 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |